104 related articles for article (PubMed ID: 3763479)
21. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
22. Dysplastic erythroid precursors in the myelodysplastic syndromes and the acute myeloid leukemias: Is there biologic significance? (How should blasts be counted?).
Bennett JM; Tuechler H; Aul C; Strupp C; Germing U
Leuk Res; 2016 Aug; 47():63-9. PubMed ID: 27258735
[TBL] [Abstract][Full Text] [Related]
23. [Myelodysplastic syndrome: a review].
Creutzig U; Hoelzer D
Klin Padiatr; 1987; 199(3):169-72. PubMed ID: 3626418
[TBL] [Abstract][Full Text] [Related]
24. Apoptotic megakaryocyte dysplasia in the myelodysplastic syndromes.
Hatfill SJ; Fester ED; Steytler JG
Hematol Pathol; 1992; 6(2):87-93. PubMed ID: 1607344
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow blasts level predicts prognosis in patients with refractory cytopenia with multilineage dysplasia.
Wang H; Wang XQ; Xu XP; Lin GW
Eur J Haematol; 2009 Dec; 83(6):550-8. PubMed ID: 19737310
[TBL] [Abstract][Full Text] [Related]
26. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
27. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
28. Topics in bone marrow biopsy pathology: role of marrow topography in myelodysplastic syndromes and evaluation of post-treatment and post-bone marrow transplant biopsies.
Reddy VV
Ann Diagn Pathol; 2001 Apr; 5(2):110-20. PubMed ID: 11294998
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndromes: the complexity of stem-cell diseases.
Corey SJ; Minden MD; Barber DL; Kantarjian H; Wang JC; Schimmer AD
Nat Rev Cancer; 2007 Feb; 7(2):118-29. PubMed ID: 17251918
[TBL] [Abstract][Full Text] [Related]
30. Terminal deoxynucleotidyl transferase-positive cells in trephine biopsies following bone marrow or peripheral stem cell transplantation reflect vigorous B-cell generation.
Wolf E; Harms H; Winkler J; Reulbach U; Kirchner T; Niedobitek G; Baumann I
Histopathology; 2005 Apr; 46(4):442-50. PubMed ID: 15810956
[TBL] [Abstract][Full Text] [Related]
31. [Importance of immunomorphometric evaluation of the size and number of megakaryocytes in normal and pathologic bone marrow].
Marisavljević D; Rolović Z; Mitrović D
Srp Arh Celok Lek; 1993; 121(3-7):57-61. PubMed ID: 7716637
[TBL] [Abstract][Full Text] [Related]
32. [Pattern analytic investigations of blast cells in myelodysplastic syndrome and secondary acute myeloid leukemia].
Baumann I; Harms H; Kuse R; Feller AC; Müller-Hermelink HK
Verh Dtsch Ges Pathol; 1990; 74():135-8. PubMed ID: 1708571
[TBL] [Abstract][Full Text] [Related]
33. Risk assessment in myelodysplastic syndromes: value of clinical, hematologic and bone marrow histologic findings at presentation.
Morra E; Lazzarino M; Castello A; Inverardi D; Coci A; Alessandrino EP; Brusamolino E; Bernasconi P; Orlandi E; Bonfichi M
Eur J Haematol; 1990 Aug; 45(2):94-100. PubMed ID: 2209826
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical evaluation of bone marrow biopsies in myelodysplastic syndromes.
Soligo D; Luksch R; Quirici N; Foa P; Moneta D; Somalvico F; Lambertenghi Deliliers G
Haematologia (Budap); 1991; 24(1):39-46. PubMed ID: 1813362
[TBL] [Abstract][Full Text] [Related]
35. Clinical, hematological and histomorphological profile of myelodysplastic syndrome.
Nigam S; Rani S; Singh T; Gupta S; Rakheja D; Gaiha M
J Assoc Physicians India; 2001 Apr; 49():430-4. PubMed ID: 11762613
[TBL] [Abstract][Full Text] [Related]
36. Bone marrow histology in myelodysplastic syndromes. I. Histological findings in myelodysplastic syndromes and comparison with bone marrow smears.
Tricot G; De Wolf-Peeters C; Hendrickx B; Verwilghen RL
Br J Haematol; 1984 Jul; 57(3):423-30. PubMed ID: 6589011
[TBL] [Abstract][Full Text] [Related]
37. [Cytogenetic examination of bone marrow cells in stem cell diseases of myelodysplastic syndromes].
Werner M; Maschek HJ; Kaloutsi V; Buhr T; Kausche F; Delventhal S; Georgii A
Verh Dtsch Ges Pathol; 1990; 74():139-43. PubMed ID: 1708572
[TBL] [Abstract][Full Text] [Related]
38. High-level CD34 expression on megakaryocytes independently predicts an adverse outcome in patients with myelodysplastic syndromes.
Tang G; Wang SA; Menon M; Dresser K; Woda BA; Hao S
Leuk Res; 2011 Jun; 35(6):766-70. PubMed ID: 21367453
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis in myelodysplastic syndromes.
Pruneri G; Bertolini F; Soligo D; Carboni N; Cortelezzi A; Ferrucci PF; Buffa R; Lambertenghi-Deliliers G; Pezzella F
Br J Cancer; 1999 Dec; 81(8):1398-401. PubMed ID: 10604739
[TBL] [Abstract][Full Text] [Related]
40. [Diagnostic value of dysplasia characteristics in typing of myelodysplastic syndrome].
Li J; Zhang M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):657-61. PubMed ID: 23815917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
